mouse genome (Abelson & Rabstein, 1970) . The only product coded by A-MuLV is a hybrid protein (P160gag-abl) which possesses a tyrosine kinase activity (Sefton et al., 1981) and is considered responsible for the oncogenic potential of A-MuLV (Witte et al., 1978) .
A-MuLV transforms in vitro lymphoid cells (Rosenberg et al., 1975) as well as fibroblasts (Scher & Siegler, 1975) , while in vivo induces lymphomas which are most frequently of the pre-B cell phenotype (see review by Risser, 1982) . However, it is possible to induce thymic lymphomas by injecting the virus intrathymically (Cook, 1982) . Previous studies (Cook, 1982 (Cook, , 1985 Risser et al., 1985; Saggioro et al., 1985 Saggioro et al., , 1986 Scott et al., 1986; D'Andrea et al., 1987) indicated that cells derived from A-MuLV induced thymic lymphomas are very immature and possess phenotypic features different from those usually expressed by pre-B lymphoid cells involved in A-MuLV induced lymphomas.
The rapid induction of lymphomas in vivo and the direct transformation of fibroblasts in vitro suggest that A-MuLV can induce malignant transformation in a single step fashion by means of its tyrosine kinase activity. However, in some in vitro systems, A-MuLV integration and expression does not necessarily result in an indefinite ability to grow (Rosenberg & Baltimore, 1976; Whitlock et al., 1983) and, following AMuLV injection, it has been demonstrated that only a few of the infected bone marrow cells are transformed (Green et al., 1987) .
As part of a larger study aimed to characterize the AMuLV target cells within the thymic tissue, we report here the in vivo and in vitro growth properties of A-MuLV transformed cell lines obtained by injecting the virus directly in the thymus of newborn BALB/c and C57BL/6 mice. Cell lines of C57BL/6 origin showed a limited in vitro growth ability and lack of tumorigenicity in syngeneic immunocompetent hosts soon after their establishment in vitro from primary tumours. After continuous in vitro growth, progression towards a more malignant phenotype was observed in one cell line (TB6-3). No substantial differences in A-MuLV integration patterns, v-abl specific mRNA expression, and P160gag-abl could be detected before and after progression in TB6-3 cells implying that the activity of a single oncogene Correspondence: D. Saggioro. Received 19 November, 1987; and in revised form 18 February, 1988. (v-abl) might not be sufficient for full malignant transformation.
Materials and methods
Mice BALB/c and C57BL/6 (B6) mice were originally purchased from The Jackson Laboratory (Bar Harbor, ME, USA) or Charles River Laboratories (Calco, Como, Italy) and maintained in our colony for several generations by sister x brother matings.
Virus
ABC-1, a pre-B A-MuLV transformed cell line (Teich et al., 1979) , was the source of the A-MuLV(M-MuLV) complex. Three to 4 x 106 ABC-I cells were injected s.c. in syngeneic BALB/c mice and from the transplanted tumour mass, a cell free extract was prepared as already described (ChiecoBianchi et al., 1974) . The A-MuLV titre (3.5 x 103 FFU/ml) was determined by focus formation on NIH 3T3 fibroblasts (Scher & Siegler, 1975) ; the helper M-MuLV was titrated by UV-XC plaque assay (Rowe et al., 1970) .
Cell lines and culture medium TA-2, TA-3 (H-2d), and TB6-1, TB6-2, TB6-3 (H-2b) cell lines were established in vitro from primary thymic lymphomas induced by injecting A-MuLV intrathymically (i.t.) in newborn BALB/c (H-2d) and B6 (H-2b) mice respectively (Saggioro et al., 1986; D'Andrea et al., 1987) . YC8 (H-2d) (Leclerc et al., 1972 ), MBL-2 (H-2b) (Glynn et al., 1968) and TB-5 (H-2d) (Saggioro et al., 1986) are established cell lines derived from M-MuLV induced lymphomas.
All lymphoma cell lines were cultured in complete medium consisting of Dulbecco-MEM (GIBCO, Europe, Glasgow, UK) supplemented with 2x 10-3M L-glutamine, 3 x 10-2M HEPES, 5 x 10-5M 2-mercaptoethanol, antibiotics and 10%
heat-inactivated foetal calf serum (FCS) (GIBCO).
Western blot analysis Five million cells were lysed directly in Laemmli buffer and subjected to SDS polyacrylamide gel electrophoresis (Laemmli, 1970) ; Western blot analysis was carried out according to the method of Towbin et al. (1979) and as previously described (Saggioro et al., 1986 Southern (1975) . Filters were hybridized overnight to a nick translated probe (Rigby et al., 1977) as already described (D'Andrea et al., 1987) . The 2.0kb v-abl specific probe used in this study was derived from the pAB3Sub3 plasmid (Goff et al., 1980) with the use of the restriction enzymes Sma I and Hind III.
Generation of virus specific cytotoxic T lymphocytes Cytotoxic T lymphocytes (CTL) were generated in vitro by using a mixed leukocyte tumour cells culture (MLTC) as previously described (Collavo et al., 1978 (Collavo et al., 1978) ; either TB6-3 and TA-2 cells or the transplantable MBL-2 and YC8 lymphoma cells were used as stimulator cells, for the B6 and BALB/c mouse system, respectively. The cytotoxic activity of CTL was tested as previously described (Collavo et al., 1978) , and its specificity analysed using normal Concanavalin A (ConA) blasts as negative controls.
Conditioned media Conditioned media (CM) from TA-2 and TB6-3 cell lines were obtained by growing the cells (5 x 105 ml-1) in medium containing 1% FCS. After 3 days, the media were centrifuged at 400g to pellet the cells and clarified from the virus at 100,000g. The supernatants were then filtered through a 0.2jm Millipore membrane.
Tritiated thymidine (3H-TdR) incorporation assay For the determination of the DNA-synthesis rate, 2 x 103 cells/well were incubated in the presence of scalar doses of CM in medium containing 1% FCS when using the TB-5 cell line, or 10% FCS when using the CTL-L cell line and thymocytes. After 48-72 h, 3H-TdR (specific activity: 1 mCi ml-) was added and left overnight; the cells were then harvested and the incorporation of 3H-TdR determined using a beta-counter. Three to four bands corresponding to acquired abl sequences were detected in all cell lines through Southern blot analysis (D'Andrea et al., 1987) and an approximately equal amount of abl mRNA was detected in the cell lines as shown in Figure 1 . The data obtained by Northern blot analysis were confirmed by Western blot experiments in which the gag-abl specific protein was detected along with the structural proteins of the helper M-MuLV, using an anti M-MuLV serum ( Figure 2 ). In fact, all cell lines were productively infected by the A-MuLV(M-MuLV) complex, since culture supernatants tested for the presence of infectious virus were able to induce foci in NIH 3T3 fibroblasts as well as plaques in the UV-XC test (data not shown). Table I , the BALB/c cell lines (TA-2 and TA-3) were highly tumorigenic since even a low dose (5 x 103 cells) induced tumours in 80 to 100% of recipient mice. On the contrary, cells of B6 origin (TB6-1, TB6-2 and TB6-3) were not able to grow in syngeneic recipients even when injected at high dose (107 cells). However, when TB6-3 cells were inoculated in sublethally irradiated (5.5Gy) B6 mice, they invariably killed the host within a short period of time (14 days). In addition, when B6 mice, which did not exhibit any tumour growth after syngeneic lymphoma cell inoculation, were challenged with a lethal dose (105) of MBL-2 cells derived from a MMuLV induced lymphoma no tumour growth was observed (data not shown). Similarly, no tumour development was noticed when the few BALB/c mice which escaped death after injection of a low dose of TA-3 cells (see Table I ), were reinoculated with a lethal dose (106) (Leclerc et al., 1972) . Thus, to further assess the viral specificity of the host immune response, effector spleen cells from M-MSV regressor B6 or BALB/c mice (Collavo et al., 1978) , were stimulated with MBL-2 (H-2b) or YC8 (H2d) (M-MuLV lymphoma cell lines) respectively. CTL generated in this way were able to lyse A-MuLV as well as MMuLV lymphoma cells efficienctly (see Table II ). These results confirm that A-MuLV transformed cells are highly immunogenic and are readily recognized and lysed by virus specific CTL.
In vivo and in vitro progression of lymphoma cells
In an attempt to determine whether it was possible to obtain B6 cell variants able to grow in adult syngeneic immunocompetent mice, a few clones were derived from the nontumorigenic TB6-3 cells by limiting dilution. When tested for oncogenicity, all four TB6-3 clones grew and killed the host although they exhibited a different degree of malignancy (the mean survival time of injected mice varying from 20 to 59 days) (Table III) . Furthermore, when the TB6-3 cells, which were maintained continuously in culture during clone isolation, were reinoculated into untreated mice they were able to kill 75% of injected mice in a short period of time (20 days) (Table III) . It should be mentioned that no phenotypic changes were observed in TB6-4 and TB6-2 cells which did not become tumorigenic after continuous in vitro growth. The acquisition of growth capacity in vivo by TB6-3 cells and its clones was not accompanied by substantial changes in AMuLV integration patterns ( Figure 3A) or v-abl specific mRNA expression ( Figure 3B ). Moreover, no loss of susceptibility to lysis in vitro by specific CTL was observed (data not shown). Thus, the increased tumorigenicity observed after in vitro passages could imply a cellular progression toward a more malignant phenotype not linked to additional A-MuLV integrations or to variations in immunogenicity and immunosensitivity.
On the other hand, the malignant progression of the TB6-3 lymphoma cell line observed in vivo was accompanied by an in vitro loss of requirement for exogenous growth factor(s) (Table III) , a property also shared by TA-2 cells. In fact, after 7-9 months of growth in vitro, TB6-3 cells, which were sensitive to the FCS concentration soon after their establishment in vitro, were afterwards able to grow in 1 % FCS medium, like TA-2 cells. A further analysis of TB6-3 and TA-2 cell lines showed that their growth in vitro was dependent on the cell concentration since optimal growth at low serum concentration (1-2%) was achieved only when at least 105 cells/well were plated; less than 50% of cell growth was observed at 104 cells/well in presence of the same FCS concentration (Figure 4) . This raises the possibility that A- Mitogenic activity of conditioned media In order to see whether A-MuLV lymphoma cells produce and secrete a mitogenic factor(s), serial dilutions of conditioned media (CM) from TB6-3 and TA-2 cell lines were tested. First, we analysed whether cells from these lines release normal lymphokines such as IL-1 and IL-2. Any attempt to induce stimulation of growth (evaluated by 3H-TdR incorporation) in normal, freshly isolated thymocytes (Krakauer et al., 1982) and in the IL-2 dependent CTL-L cell line (Gills et al., 1978) grown in the presence of CM from TB6-3 and TA-2 cultures, was unsuccessful (data not shown). On the contrary, when CM from TB6-3 and TA-2 cultures were tested on the M-MuLV lymphoma TB-5 cell line, which is not responsive to either IL-1 or IL-2 (data not shown), a significant increase in DNA synthesis was observed (Table IV) .
These results support the hypothesis that A-MuLV transformed cell lines might specifically release factor(s), different from IL-1 and IL-2, which not only stimulates their own growth but is able to induce DNA synthesis in other lymphoma cells.
Discussion
During tumour progression many genotypic (Nowell, 1986) and/or phenotypic (Nicolson, 1987) through still poorly defined mechanism(s) (Schirrmacher, 1985) .
In our system various factors, inherent to both host immune response and growth potential of the cells, appear to contribute to the tumorigenic behaviour of A-MuLV lymphoma cells. These cells, like most virus transformed cells, are highly immunogenic and able to stimulate the host immunity. In B6 mice, which are known to be highly responsive to A-MuLV antigens (Risser et al., 1985) , the lack of in vivo growth of TB6-3 cells is likely to be attributable to a virus-specific cell mediated immune response rather than to the inability of cells to grow, since the same cells were able to kill all the immunosuppressed animals. However, after a long period of in vitro cultivation, the TB6-3 cell line as well as its clones were able to grow in immunocompetent hosts. Apparently, the malignant cells were not variants which had lost their immunogenic potential since they were still H-2 positive and behaved in vitro as targets for specific CTL (data not shown).
Progression to a more malignant phenotype was accompanied by loss of requirement for exogenous growth factor(s) when cells were plated at high density (Figure 4) . Thus, the tumorigenic potential of A-MuLV transformed cells is related not only to the immune response of the animal but also to their growth potential. This could also be the case for TA-2 cells, (a BALB/c derived cell line), which were highly malignant despite their immunogenicity (see Tables I and II) .
The cell concentration dependent fashion of growth in vitro suggests the involvement of an autocrine mechanism of proliferative stimulation (Sporn & Todaro, 1980) . The activation of autocrine loops has been demonstrated in other spontaneous and induced haematopoietic tumours (Gordon et al., 1984; Hays et al., 1984; Haas et al., 1986) as well as in fibroblasts transformed by A-MuLV (Twardzik et al., 1982; Gebhardt et al., 1986) . On the contrary, three recent studies provide evidence for non-autocrine mechanisms of growth in mast cells and myeloid cells infected with A-MuLV (Cook et al., 1985; Pierce et al., 1985; Oliff et al., 1985) . In our system the finding that conditioned media (CM) from the TA-2 and It is possible that the observed malignant progression is the result of selection of a minor subpopulation already present in the primary thymic lymphoma, with a capacity for unrestricted growth. However, the genomic stability observed in v-abl integration and expression patterns ( Figure 3A, B) argttes against a clonal selection hypothesis of variants among TB6-3 cells. The in vitro progression could be the result of secondary changes which further alter the in vivo and in vitro growth properties of the whole cell population. The role of the abl oncogene in promoting these secondary events is unknown and might not be due to genetic alterations.
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